Dogwood Therapeutics Inc Ordinary Shares DWTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Dogwood Therapeutics Announces Third Quarter 2026 Financial Results
Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.
Dogwood to Participate in the 2026 Maxim Growth Summit
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
Trading Information
- Previous Close Price
- $1.04
- Day Range
- $1.09–1.19
- 52-Week Range
- $0.90–7.04
- Bid/Ask
- $1.04 / $1.13
- Shares Outstanding
- 38.23M
- Market Cap
- $45.49M
- Volume/Avg
- 1,848 / 78,391
Key Statistics
- Price/Earnings (Normalized)
- 0.39
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.virios.com
Valuation
Metric | DWTX |
|---|---|
Price/Earnings (Normalized) | 0.39 |
Price/Book Value | 0.51 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
DWTX
Financial Strength
Metric | DWTX |
|---|---|
Quick Ratio | 3.39 |
Current Ratio | 3.89 |
Interest Coverage | — |
Quick Ratio
DWTX
Profitability
Metric | DWTX |
|---|---|
Return on Assets (Normalized) | −19.31% |
Return on Equity (Normalized) | −50.82% |
Return on Invested Capital (Normalized) | −23.15% |
Return on Assets
DWTX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|RFw>!cf | LOCK|D&#&Y | $138B | |||
| Moderna Inc MRNA | LOCK|p<NK>>k | LOCK|fzC | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|t^&tYf | LOCK|?$PLQ | $93B | |||
| argenx SE ADR ARGX | LOCK|sL^^T?F | LOCK|nn& | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|$Q<QG% | LOCK|m# | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|@Y?y<GN< | LOCK|t!FH | $30B | |||
| Incyte Corp INCY | LOCK|NQWq@@B | LOCK|cl | $24B | |||
| BioNTech SE ADR BNTX | LOCK|^!yVNX | LOCK|fk& | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|>FkD@bR | LOCK|Vk&Np | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|Kk^y?Z% | LOCK|@^& | $15B |
United States